Release Date: November 14, 2025
Expiration Date: November 14, 2026
Activity Overview
Acute lymphoblastic leukemia (ALL) demands precise, individualized care—from risk stratification and CNS prophylaxis to selecting and sustaining asparaginase therapy. Persistent gaps include recognizing and managing hypersensitivity vs silent inactivation, preserving dose intensity, integrating MRD to guide decisions, and communicating risks/benefits with patients and families. This 3-module SimulatED™ online, on-demand program uses a case-based simulation with physician–patient dialogues, multiple-choice questions, and concise videos to translate evidence into practice. Module 1 covers diagnosis, risk stratification, CNS prophylaxis, and asparaginase eligibility; Module 2 focuses on hypersensitivity management and preserving exposure; Module 3 builds skills in empathy, teach-back, and shared decision-making. This format drives behavior change through branching decisions, immediate feedback, and clinic-ready checklists.
Target Audience
This educational activity is directed toward physicians, nurse practitioners, physician assistants, pharmacists, nurses, and other health care providers involved in the diagnosis and treatment of acute lymphoblastic leukemia.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate recent clinical trial data supporting new and improved strategies to treat patients with ALL
- Integrate personalized treatment approaches that include asparaginase therapy for patients with ALL
- Implement strategies to monitor, mitigate, and manage toxicities associated with asparaginase therapies for ALL
- Strengthen clinician-patient-caregiver communication to support informed decision-making and improve care outcomes
Jae Park, MD
Professor of Medicine
Chief, Cellular Therapy Service
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Adaptive Biotechnologies, Affyimmune Therapeutics, Allogene Therapeutics, Amgen, Artiva Biotherapeutics, Ascentage, Autolus, BeiGene, Bright Pharmaceutical Services, Inc., Caribou Bioscience, Curocell, Galapagos, Iovance, Jazz Pharmaceuticals, Kite, Medpace, Pfizer, Servier, Sobi, Synthekine, Takeda; Grant/Research Funding: Autolus, Bristol Myers Squibb, Cabaletta, Genentech
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.